title: The hazards of randomized phase II trials.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, USA. Electronic address: primo.lara@ucdmc.ucdavis.edu.
authors.forename: P N
authors.initials: PN
authors.lastname: Lara
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, USA.
authors.forename: M W
authors.initials: MW
authors.lastname: Redman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*
chemical_list: D009838:Oligodeoxyribonucleotides; C483020:ProMune